|
Patient-specific meta-analysis of 3 validation studies of the 12-gene colon cancer recurrence score assay for recurrence risk assessment after surgery with or without 5FU and oxaliplatin. |
|
|
Employment - Mountainview Pediatrics (I) |
Consulting or Advisory Role - Orbus Therapeutics |
|
|
Consulting or Advisory Role - Array BioPharma; Merck Sharp & Dohme |
Research Funding - Amgen; Bristol-Myers Squibb (Inst); Genentech/Roche (Inst) |
Patents, Royalties, Other Intellectual Property - Royalties from Now-UptoDate for authoring and maintaining two chapters |
Travel, Accommodations, Expenses - Genentech; Roche |
|
|
Honoraria - Bayer; Chugai Pharma; Takeda |
Research Funding - Bayer (Inst); Chugai/Roche (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst) |
|
|
Research Funding - Bristol Myers Squibb Foundation |
|
|
Employment - Exact Sciences |
Stock and Other Ownership Interests - Exact Sciences |
Travel, Accommodations, Expenses - Genomic Health |
|
|
Employment - Exact Sciences |
Leadership - Exact Sciences |
Stock and Other Ownership Interests - Exact Sciences |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bayer Yakuhin; Chugai Pharma; Lilly Japan; Merck; Takeda |
Research Funding - Amgen (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PAREXEL International Inc. (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst) |